Frederick Haraka

In the News

IHI names winners of research, innovation fund

[Right-Left] Getrud, Beatrice, Theckla, and Tutu.Ifakara Health Institute (IHI) has named recipients of the 2017/18 Director’s Research and Innovation Fund. This is an internal funding mechanism aimed to support specific …

Study reports boys, girls start working in the mines at 7

(Dar es Salaam, May 8, 2018). New findings of a formative study by Ifaraha Health Institute (IHI) and partners which focused on children in mining show that child miners, both …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

Frederick Haraka

Research Scientist

Dr. Frederick Haraka is a research scientist at Ifakara Health Institute, working within the Tuberculosis research group. Prior to joining the institute in 2010, Dr. Haraka obtained his Medical Degree from the Muhimbili University of Health and Allied sciences, Tanzania, in 2009, and in 2013 received his Master’s degree in Applied Epidemiology from the University of Nottingham in the UK, with merit. He is currently registered as a PhD candidate in Epidemiology at the Swiss Tropical and Public Health institute, University of Basel in Switzerland. Dr. Haraka has experience in leading and implementing Good Clinical Practice (GCP), regulated clinical trials of Tuberculosis treatment regimen, vaccines and diagnostics. He is also actively involved in designing, implementing and analysing observational studies in TB and HIV. Following this interest, Dr. Haraka has numerous publications in both local and international journals focused around issues on TB and HIV. Dr. Haraka is currently a site Principal Investigator, leading a phase 2 multi-centre TB treatment regimen trial funded and sponsored by Global alliance for tuberculosis drug development, titled “A Phase 2 Open‐Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide during 8 weeks of treatment in Adult Subjects with Newly Diagnosed Drug‐Sensitive or Multi Drug‐Resistant, Smear‐Positive Pulmonary Tuberculosis”. Beyond his scientific research, Dr Haraka is a part-time lecturer at International Medical and Technological University and Hubert Kairuki Memorial University, and mentor to junior researchers in the Institutes TB research group.

View Dr. Haraka’s Research Interests & Publications


Evaluation of Cepheid GeneXpert Omni combined with the Xpert MTB/RIF Ultra in Primary Health Care in Tanzania

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Tanzania lung health study: prevalence and risk of chronic obstructive pulmonary disease

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

© Ifakara Health Institute (IHI), 2016